Ganirelix API (CAS No. 124904-93-4) is a synthetic decapeptide and potent gonadotropin-releasing hormone (GnRH) receptor antagonist associated with fertility, reproductive medicine, and controlled ovarian stimulation pharmaceutical applications.
Ganirelix is structurally derived from naturally occurring GnRH through amino acid substitutions designed to produce strong antagonistic activity at the GnRH receptor. It competitively blocks GnRH receptors on pituitary gonadotroph cells and rapidly suppresses the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Unlike GnRH agonist-based approaches, Ganirelix produces direct receptor antagonism without an initial gonadotropin flare effect. Its rapid and reversible suppression of gonadotropin secretion makes Ganirelix-related pharmaceutical materials important in assisted reproductive technology and controlled ovarian stimulation development.
Pharmaceutical and peptide companies sourcing Ganirelix API commonly evaluate peptide identity, assay, chromatographic purity, peptide-related substances, amino acid sequence, peptide content, water content, acetate or counter-ion content where applicable, residual solvents, residual reagents, and batch-to-batch consistency.
Because Ganirelix is a synthetic peptide containing multiple defined stereochemical centers, peptide sequence integrity and stereochemical control are critical quality considerations. Pharmaceutical buyers may also evaluate deletion sequences, truncated peptides, epimer-related impurities, oxidation products, and other peptide synthesis-related impurities.
Swapnroop Drugs and Pharmaceuticals supplies Ganirelix API for qualified pharmaceutical research, peptide development, analytical, fertility drug development, and regulated manufacturing requirements with product-specific quality documentation, peptide-appropriate packaging, and reliable supply-chain coordination.
Pharmaceutical and peptide companies evaluating Ganirelix API commonly focus on:
Peptide-related impurity control is particularly important for Ganirelix because solid-phase or other peptide synthesis processes may generate closely related sequence impurities that require appropriate chromatographic characterization and control.
Stereochemical integrity is also an important buyer consideration because Ganirelix contains multiple chiral amino acid residues and defined D- and L-amino acid configurations.
Ganirelix API is primarily associated with:
Ganirelix-related pharmaceutical products are associated with inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix is a GnRH receptor antagonist associated with controlled ovarian stimulation and assisted reproductive pharmaceutical applications.
Pharmaceutical companies evaluating Ganirelix API may review:
Product-specific specifications should be evaluated according to the exact Ganirelix material form, intended dosage form, target regulatory market, and approved pharmaceutical development requirements.
Ganirelix and Ganirelix Acetate should be treated as separate product identities for website, procurement, and specification purposes.
Ganirelix free peptide is identified by CAS No. 124904-93-4.
Ganirelix Acetate is identified by CAS No. 129311-55-3 and is the active substance associated with marketed subcutaneous injection products.
FDA labeling describes Ganirelix Acetate as a synthetic decapeptide with high antagonistic activity against naturally occurring GnRH.
Procurement, formulation, quality, and regulatory teams should confirm the exact peptide or acetate form before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and peptide-development customers with:
Ganirelix API is supplied in secure peptide-appropriate pharmaceutical packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate primary containers and protective secondary packaging may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, storage requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Ganirelix API under the controlled storage conditions specified in the approved product documentation.
Protect the peptide material from excessive moisture, heat, direct light, contamination, and unsuitable environmental exposure.
Repeated temperature excursions should be avoided where restricted by the product-specific stability specification.
Handling should be performed by trained personnel using approved peptide and pharmaceutical raw material handling procedures and applicable safety documentation.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Swapnroop Drugs and Pharmaceuticals provides Ganirelix API bulk supply and export support in India for qualified pharmaceutical manufacturers, fertility drug developers, peptide companies, analytical laboratories, research organizations, and pharmaceutical procurement customers.
Get Bulk Quote via WhatsApp